Infections in hematologic malignancy patients treated by CD19 chimeric antigen receptor T‐cell therapy

Infections in hematologic malignancy patients treated by CD19 chimeric antigen receptor T‐cell therapy

Abstract Increasing use of chimeric antigen receptor‐T (CAR‐T) cell therapy has significantly improved the survival of hematologic malignancy patients, but CAR‐T cell treatment is also associated with increased risk of infection. Hence, understanding the characteristics of infection may improve dise...

Full description

Bibliographic Details
Main Authors: Linghui Zhou, Elaine Tan Su Yin, Houli Zhao, Shuyi Ding, Yongxian Hu, He Huang
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:ImmunoMedicine
Subjects:
axicabtagene ciloleucel
CAR‐T
infection
tisagenlecleucel‐T
Vigibase
Online Access:https://doi.org/10.1002/imed.1036

Internet

https://doi.org/10.1002/imed.1036

Similar Items